LONG NAGOMI™ PMCF STUDY

Other illness

• Patients with acute coronary syndrome (ACS) under conditions of cardiogenic shock (Killip class 4).
• Patients with contraindications or hypersensitivity to sirolimus.

Lab values

• Patients in whom any surgery requiring general anesthesia is planned, comorbidity or indication likely necessitating the discontinuation of dual anti-platelet therapy before the recommended duration of dual anti-platelet therapy per the ESC or national guidelines.

Other

• Patients must not meet any of the following exclusion criteria:
• Patients who expressly decline to participate in the study.
• Pregnant or breastfeeding women.
• Patients with a life expectancy of less than 2 years.
• Patients included in other clinical trials that did not reach the primary objective.

• Patients who meet ALL inclusion criteria will be included:
• Patients aged ≥ 18 years AND;
• Patients who according to standard practice of the hospital are amenable to PCI as indicated and considered adequate according to the European clinical practice guidelines on coronary revascularization AND;
• Patients with at least one lesion fulfilling the "long lesion criteria" suitable for a single stent approach AND;
• Patients who have been informed of the characteristics of the study and have provided written informed consent AND;
• Intention to treat all lesions with the Ultimaster Nagomi™ stent